arGEN-X « Terug naar discussie overzicht

arGEN-X Nieuws 2017

568 Posts, Pagina: 1 2 3 4 5 6 ... 25 26 27 28 29 » | Laatste
[verwijderd]
0
Nieuw draadje om de moed er in te houden. De kop is eraf en koers springt van hot naar her. Vanaf de top is er bijna €1,75 af.
Beetje vastklampen aan het laatste advies van KBC dan maar?
Fermín Romero de Torres
0
Volume stelt ook weinig voor. Er is niet veel voor nodig om de koers lager te krijgen. Het is wachten op nieuws. Weet iemand wat we kunnen verwachten de komende maanden?
[verwijderd]
0
Is inderdaad op laag volume behoorlijk gedaald de laatste weken . Waarschijnlijk wat winstnemingen van kleine particulieren . De grote jongens zijn blijven zitten of hebben uitgebreid en dat is belangrijker . Ik heb ook niets verkocht . Argen-X kan wel eens een zeer grote verrassing gaan worden als je ziet wat een potentiële blockbusters ze in de pipeline hebben . Ik denk dat we dit jaar nog een nieuwe mooie partnership kunnen verwachten . ( Celgene lijkt een logische mogelijkheid )
[verwijderd]
0
argen-x.com/en-GB/news-internal/argen...

We are very committed to our recently initiated Phase I/II study of ARGX-110 in combination with standard of care azacitidine as we believe this target represents an innovative and differentiated approach to the disease, further proven by this seminal data underscoring the role of CD70 in acute myeloid leukaemia (AML).”
** Azacitidine (Vidaza®, Celgene)- **

Het kunnen natuurlijk ook andere partners worden .

argen-x.com/en-GB/news-internal/argen...

Hieronder een bericht van october 2016 van Seeking Alpha . mooie vergelijking met GLPG en Ablynx
seekingalpha.com/article/4012637-arge...


[verwijderd]
0
Mooi nieuws .

verdere samenwerking met Shire .

Published: 07:00 CET 27-02-2017 /GlobeNewswire /Source: argenx N.V. / : ARGX /ISIN: NL0010832176

argenx announces extension of therapeutic antibody alliance with Shire




Breda, the Netherlands / Ghent, Belgium - argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the extension of its strategic partnership with Shire plc (NASDAQ: SHPG) to advance the discovery and development of novel human therapeutic antibodies for diverse rare and unmet diseases for a further year until May 30, 2018.



"The productivity of our collaboration with Shire has presented exciting product development opportunities in previously untapped target territory", said Debbie Allen, Senior VP Business Development of argenx. "Extension of this partnership provides both parties the potential to treat the pathophysiology of rare genetic diseases with potentially first-in-class antibody products".



About the strategic alliance with Shire



Under the terms of the agreement extension announced today, the parties will continue to progress preclinical development of the most promising programs to have arisen from the collaboration to date. Upon attainment of specified development criteria, Shire may exercise options - accompanied by a milestone payment to argenx on a per program basis - to take over product development and commercialization. argenx will thereafter receive milestone payments as programs proceed through clinical development and royalties on eventual product sales. argenx shall have the right to in-license any products falling outside Shire's areas of focus on pre-agreed financial terms. Further details of the extension agreement were not disclosed.



The initial agreement between Shire and argenx commenced in 2012 and was expanded into a strategic alliance in 2014 granting Shire licenses to the entire suite of argenx discovery technologies. argenx has received licensing fees, research funding, and milestone payments from this collaboration.



About argenx

argenx is a clinical-stage biotechnology company with a deep pipeline of differentiated antibody-based therapies intended for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates that are either first-in-class against novel targets or best-in-class against known, but complex, targets to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies enable us to expand the therapeutic index of our product candidates.

www.argenx.com



For further information, please contact:

Joke Comijn, Corporate Communications and Investor Relations Manager

+32 (0)477 77 29 44

+32 (0)9 310 34 19

info@argenx.com



Beth DelGiacco (US IR)

Stern Investor Relations

+1 212 362 1200

beth@sternir.com


[verwijderd]
0
Published: 07:00 CET 28-02-2017 /GlobeNewswire /Source: argenx N.V. / : ARGX /ISIN: NL0010832176

argenx to Present at Cowen & Co 37th Annual Health Care conference




Breda, the Netherlands / Ghent, Belgium- argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that its Chief Executive Officer Tim Van Hauwermeiren Chief Executive Officer, will present a company overview at the Cowen & Co. 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 8:00 a.m. ET at the Boston Marriott Copley Place.



About argenx

argenx is a clinical-stage biotechnology company with a deep pipeline of differentiated antibody-based therapies intended for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates that are either first-in-class against novel targets or best-in-class against known, but complex, targets to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies enable us to expand the therapeutic index of our product candidates.

www.argenx.com



For further information, please contact:

[verwijderd]
0
Published: 19:00 CET 01-03-2017 /GlobeNewswire /Source: argenx N.V. / : ARGX /ISIN: NL0010832176

argenx announces intention to conduct a registered public offering in the United States




Breda, the Netherlands / Ghent, Belgium - argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission relating to the proposed registered public offering of its ordinary shares in the United States. The timing, number of ordinary shares and price of the proposed offering have not yet been determined.



This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.



About argenx

argenx a clinical-stage biotechnology company with a deep pipeline of differentiated antibody-based therapies intended for the treatment of severe auto-immune diseases and cancer. We are focused on developing product candidates that are either first-in-class against novel targets or best-in-class against known, but complex, targets to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies enable us to expand the therapeutic index of our product candidates.

www.argenx.com

[verwijderd]
0
quote:

de speurneus schreef op 1 maart 2017 22:51:


Nasdaq notering in de maak.


Normaal ben ik niet zo van de Nasdaqnoteringen bij jonge bedrijven .
Bij Argen-X heb ik het gevoel dat het wel goed zit . Ze hebben werkelijk de wind in de zeilen . Productontwikkelingen gaan snel . Veel goede partnerships / potentiële blockbusters / pipeline ontwikkelingen / goed management / koersontwikkeling .

Ik denk dat er een hoop Amerikaanse institutionele beleggers interesse zullen hebben .
Voor Argen-X uitgelezen kans om hun pipeline te versnellen/ bescherming tegen overname / betere onderhandelingspositie bij eventuele nieuwe partnerships/ naamsbekendheid etc .

Ik had het niet verwacht , maar Argen-X is qua snelheid en ontwikkeling Ablynx voorbij gestoven op dit moment . Beide bedrijven voor mij een duidelijke LT in mijn port.
[verwijderd]
0
De vraag is wat de uitgifte prijs wordt. Als argen-x net zo'n ontwikkeling doormaakt als Merus bv dan mogen we in onze handjes vrijwen.
[verwijderd]
0
argenx announces that Staten Biotech exercised its option to develop therapeutic SIMPLE AntibodyTM for
argenx N.V.
Published: 07:00 CET 06-03-2017 /GlobeNewswire /Source: argenx N.V. / : ARGX /ISIN: NL0010832176

argenx announces that Staten Biotech exercised its option to develop therapeutic SIMPLE AntibodyTM for dyslipidemia



-Anti-ApoC3 antibody developed as part of research collaboration on dyslipidemia-
- Represents latest collaboration to stem from the argenx's Innovative Access Program-
-argenx is eligible to receive a double-digit royalty on ARGX-116 related income-

6 March 2017

Breda, the Netherlands/Ghent, Belgium argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that Staten Biotech has exercised its exclusive option to license ARGX-116, an anti-ApoC3 SIMPLE AntibodyTM with therapeutic potential in dyslipidemia. This collaboration is the latest to stem from the argenx Innovative Access Program.

"The discovery of ARGX-116 is truly one of collaboration, utilizing Staten's unique expertise in dyslipidemia and our novel SIMPLE AntibodyTM platform to develop an antagonizing antibody against ApoC3, a target involved in triglyceride metabolism," commented Tim Van Hauwermeiren, Chief Executive Officer of argenx. "We are highly encouraged by Staten's decision to pursue further development of this exciting molecule and recognize that strategic collaborations like this one are a fundamental pillar of our mission allowing us to be a leader in developing therapeutic antibodies."

argenx began its collaboration with Staten Biotech in 2015 as part of a research collaboration through its Innovative Access Program. Under the terms of the agreement, Staten will be responsible for additional development of ARGX-116, and argenx is eligible to receive a double-digit portion on income related to the product. Additional financial details of the collaboration have not been disclosed.

About the Innovative Access Program
Through our Innovative Access Program (IAP) argenx is able to serially collaborate closely with academic experts and small biotech companies, bringing antibody discovery technologies to the heart of novel target research. The IAP allows our partners use of our technologies for the development of antibodies to help validate novel targets. In return argenx is granted early access to these targets. The diversity of argenx's SIMPLE AntibodyTM immune repertoires streamlines target validation, with the potential to transform novel proteins into next generation therapeutic antibody programs.

About ApoC3
ApoC3 is protein with several modes of action: it inhibits very-low-density-lipoproteins (VLDL) uptake by the liver and it inhibits the activity of lipoprotein lipase leading to high levels of lipoproteins and triglycerides. Loss of function mutations in ApoC3 leads to reduced incidence of vascular and heart diseases. This supports the potential of the anti-ApoC3 antibody to act as key molecule in dysplipidemia management.

About Staten
Staten Biotechnology aims to develop novel and innovative strategies for the treatment of dyslipidemia, namely in the triglyceride space. Staten Biotechnology B.V. is incorporated in 2014 by world experts in dyslipidemia, Paul da Silva Jardine, Daniel Rader and Alan Tall. Daniela Couto is the Managing Director.

About argenx
argenx a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.
www.argenx.com

For further information, please contact:

Joke Comijn, Corporate Communications and Investor Relations Manager
+32 (0)477 77 29 44
+32 (0)9 310 34 19
info@argenx.com

Beth DelGiacco (US IR)
Stern Investor Relations
+1 212 362 1200
beth@sternir.com

Forward-looking Statements
The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements argenx makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements. argenx undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.





This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: argenx N.V., Willemstraat 5, Breda 4811 AH, The Netherlands
If you would like to unsubscribe and stop receiving these e-mails click here.
[verwijderd]
0
Voor degene die niet weten wat dyslipidemia is .

Wat is dyslipidemie?

Met dyslipidemie wordt een verstoorde verhouding van vetstoffen (cholesterol) in het bloed bedoeld. Bij dyslipidemie zijn het totaalcholesterol en/ of het LDL-cholesterol en/ of de triglyceriden verhoogd en/ of is er sprake van een verlaagd gehalte van het HDL-cholesterol. Dyslipidemie is vaak een voorbode van hart- en vaatziekten en diabetes type-2. Mannen en vrouwen hebben even veel kans op het krijgen van dyslipidemie.

Cholesterol

Cholesterol is een vetachtige stof en noodzakelijke bouwsteen voor de opbouw van hormonen en lichaamscellen. Zonder cholesterol kunnen we niet leven maar een te hoog cholesterol brengt gezondheidsrisico’s met zich mee. De lever is zelf in staat om cholesterol aan te maken maar cholesterol bevindt zich ook in bepaalde voeding. Er zijn twee soorten cholesterol:

LDL-cholesterol
HDL-cholesterol
Er werd een poosje gezegd dat LDL-cholesterol slechte cholesterol was en HDL-cholesterol goede cholesterol. Echter is nu bekend dat vooral een scheve verhouding van de twee soorten cholesterol een verhoogd risico van slagaderverkalking met zich meebrengt. Slagaderverkalking verhoogt het risico op hart- en vaatziekten.

Wat is de oorzaak van dyslipidemie?

De oorzaak van dyslipidemie is een verhoging van het LDL-cholesterolgehalte en een verlaging van het HDL-cholesterolgehalte. Hierdoor ontstaat er een disbalans in de verhouding van de vetstofwisseling. Het totale cholesterolgehalte is bij mensen met dyslipidemie sterkt verhoogd. Het is nog niet exact bekend waarom sommige mensen een te hoog totaal cholesterolgehalte ontwikkelen en anderen niet. Wel zijn er sterke aannames dat een ongezonde levensstijl een te hoog cholesterol kan veroorzaken. Factoren die de kans op dyslipidemie vergroten zijn:

Roken
Weinig lichaamsbeweging
Een dieet met veel verzadigd vet
Hoge alcohol consumptie
Familiaire aanleg
Overgewicht
Diabetes type 2
Medicatie
Nierziekten
Leverziekte
Een traag werkende schildklier
Symptomen van dyslipidemie

Het gevaar van dyslipidemie is dat veel mensen in het algemeen geen tot weinig symptomen krijgen. Een te hoog totaal cholesterolgehalte wordt meestal pas opgemerkt als hierdoor andere aandoeningen zoals diabetes type 2 en hart- en vaatziekten zijn ontstaan. Het is daarom erg belangrijk dat bij mensen die tot de risicogroep behoren regelmatig het cholesterolgehalte wordt gemeten.

Diagnose van dyslipidemie

De diagnose van dyslipidemie wordt gesteld met een bloedonderzoek waaruit het cholesterolgehalte blijkt. Een cholesterolgehalte onder de vijf is goed. Alles boven de vijf duidt op een verhoogd cholesterolgehalte en een gehalte boven de acht is een sterk verhoogd cholesterolgehalte.

Echter schommelt het cholesterolgehalte in het bloed nogal. Er zijn dus meerdere bloedonderzoeken nodig om een betrouwbaar beeld te krijgen en om vast te stellen of er sprake is van dyslipidemie.

Laatst bijgewerkt op 5 juli 2016
[verwijderd]
0
Offtopic; niet normaal hoe hard Merus Bv gaat. Vandaag weer +10%.
Veel te vroeg eruit gestapt...
[verwijderd]
0
Dit soort aandelen moet je LT houden . Zodra echte potentie wordt/is aangetoond niet meer snel verkopen .
Pokerface
1
quote:

Benny Lava schreef op 6 maart 2017 20:17:


Offtopic; niet normaal hoe hard Merus Bv gaat. Vandaag weer +10%.
Veel te vroeg eruit gestapt...


Gewoon weer instappen ;-)
[verwijderd]
0
Indrukwekkende ontwikkeling ondergaat Argen-X . Prachtig LT aandeel .




argenx reports fourth quarter business update and full year 2016 financial results

March 15, 2017

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced its fourth quarter business update and full year results for 2016, in accordance with IFRS as adopted by the European Union.

The full year results will be discussed during a conference call and webcast presentation today at 3 pm CET / 10 am EDT. To participate in the conference call, please select your phone number below, and use the confirmation code 75576807. The webcast may be accessed on the homepage of the argenx website at www.argenx.com or by clicking here.

“The past year was one of significant growth for argenx, and we have seen the momentum maintained into the first months of 2017. We continued to build our proprietary pipeline and advanced both our lead programs, ARGX-113 and ARGX-110, through key safety and early efficacy inflection points. Our early studies guided us on the attributes of each drug and enabled us to choose the indications we believe were best-suited for Phase 2 study. By the end of the first quarter, we plan to launch four proof-of-concept Phase 2 studies: MG and ITP for ARGX-113, and AML and TCL for ARGX-110,” commented Tim Van Hauwermeiren, CEO of argenx. “We were also busy outside the clinic with the start of our collaboration with AbbVie for our novel immuno-oncology product, ARGX-115, under which we received an upfront payment of $40 million and through the expansion of our shareholder base with blue-chip U.S. investors resulting in a €46 million investment over the course of 2016.”



FOURTH QUARTER 2016 AND RECENT HIGHLIGHTS

Dosed first patient with ARGX-113 in Phase 2 proof-of-concept study for treatment of myasthenia gravis (MG).
Hosted workshop in conjunction with American Society of Hematology (ASH) Annual Meeting and provided updates on clinical data from multiple ascending dose (MAD) Phase 1 study with ARGX-113 in healthy volunteers showing comparable pharmacodynamics (PD) and pharmacokinetic (PK) patterns between lower dose (10 mg/kg) and higher dose (25 mg/kg).
Initiated Phase 1/2 clinical trial in combination with standard of care, azacytidine, in newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) patients.
Published new preclinical data in Journal of Experimental Medicine on CD70/CD27 pathway that provide further biological rationale for ARGX-110 therapy for treatment of AML.
Presented further efficacy and safety data from ongoing Phase 1b study in relapsed/refractory T-cell lymphoma (TCL) patients at ASH workshop.
Announced that Staten Biotech exercised its exclusive option to license ARGX-116, an anti-ApoC3 SIMPLE AntibodyTM with therapeutic potential in dyslipidemia.
Announced the extension of our strategic partnership with Shire for a further year until May 30, 2018.
FINANCIAL HIGHLIGHTS (as on December 31, 2016) (compared to financial highlights as on December 31, 2015)

Operating income of €17.2 million (December 31, 2015: €10.0 million).
Net loss of €21.4 million (December 31, 2015: €15.3 million).
Cash position of €96.7 million (cash, cash-equivalents and current financial assets) allowing us to pursue development of our pipeline as planned.
See PDF version for all details

About argenx

argenx a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.

www.argenx.com

[verwijderd]
0
Over de toekomst zei Van Hauwermeiren dat Argen-X zal blijven werken aan de eigen pijplijn, evenals aan het verder samenwerken met een selecte groep farmaceuten en het versterken van de aandeelhoudersbasis. Verder zal Argen-X aan het einde van het lopende kwartaal vier proof-of-concept Fase 2 studies starten.


*** Dus deze maand / 2 weken nog 3-4 persberichten te verwachten ***



Flink meer omzet Argen-X Gepubliceerd op 15 mrt 2017 om 07:15 | arGEN-X (14 mrt) EUR 16,110 -0,090 (-0,56%) (ABM FN) Argen-X heeft in 2016 beduidend meer omzet gegenereerd, maar wist dit niet te vertalen naar een lager verlies. Dit bleek woensdag voorbeurs uit de kwartaalcijfers van de Belgisch-Nederlandse biofarmaceut. Argen-X zag de omzet afgelopen periode stijgen van 6,9 miljoen naar 14,7 miljoen euro. De operationele inkomsten kwamen zelfs uit op 17,2 miljoen euro, liefst 7,2 miljoen euro meer dan een jaar eerder. Operationeel leed de biofarmaceut evenwel een verlies van 21,4 miljoen euro, hetgeen een verslechtering was van de 15,6 miljoen euro een jaar eerder. Ook onder de streep waren er rode cijfers, van 21,4 miljoen euro tegenover 15,3 miljoen euro in 2015. Een sterke toename van de onderzoekskosten drukte op het resultaat. Afgelopen jaar was er een van "significante groei", aldus CEO Tim Van Hauwermeiren in een toelichting. De topman verwacht de komende negen maanden vier Fase 2 studies te kunnen starten. Eind 2016 beschikte Argen-X over een kaspositie van 96,7 miljoen euro, flink meer dan de 42,3 miljoen euro ultimo 2015. Begin deze maand liet Argen-X weten een aanvraag te hebben ingediend bij de Amerikaanse beurswaakhond Securities and Exchange Commission om een beursnotering te krijgen in New York. Over de toekomst zei Van Hauwermeiren dat Argen-X zal blijven werken aan de eigen pijplijn, evenals aan het verder samenwerken met een selecte groep farmaceuten en het versterken van de aandeelhoudersbasis. Verder zal Argen-X aan het einde van het lopende kwartaal vier proof-of-concept Fase 2 studies starten. Op de komende jaarvergadering in april zal John de Koning vertrekken en wordt Tony Rosenberg als onafhankelijk bestuurder worden voorgesteld.
568 Posts, Pagina: 1 2 3 4 5 6 ... 25 26 27 28 29 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 30 nov 2021 17:37
Koers 247,000
Verschil 0,000 (0,00%)
Hoog 251,600
Laag 244,800
Volume 197.084
Volume gemiddeld 56.818
Volume gisteren 197.084